Investmark Advisory Group LLC Buys 606 Shares of Johnson & Johnson (NYSE:JNJ)

Investmark Advisory Group LLC boosted its stake in Johnson & Johnson (NYSE:JNJ) by 3.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,474 shares of the company’s stock after acquiring an additional 606 shares during the quarter. Johnson & Johnson accounts for 1.5% of Investmark Advisory Group LLC’s portfolio, making the stock its 21st largest position. Investmark Advisory Group LLC’s holdings in Johnson & Johnson were worth $2,961,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. City National Bank of Florida MSD bought a new stake in Johnson & Johnson during the 4th quarter worth about $351,000. Inspire Trust Co. N.A. grew its stake in shares of Johnson & Johnson by 16.4% in the fourth quarter. Inspire Trust Co. N.A. now owns 28,000 shares of the company’s stock valued at $4,049,000 after buying an additional 3,937 shares in the last quarter. Mosaic Family Wealth Partners LLC increased its stake in shares of Johnson & Johnson by 2.1% during the 4th quarter. Mosaic Family Wealth Partners LLC now owns 8,004 shares of the company’s stock worth $1,158,000 after purchasing an additional 168 shares during the last quarter. Poehling Capital Management INC. grew its holdings in Johnson & Johnson by 1.7% during the fourth quarter. Poehling Capital Management INC. now owns 5,890 shares of the company’s stock worth $852,000 after purchasing an additional 100 shares during the period. Finally, 49 Wealth Management LLC acquired a new position in Johnson & Johnson during the fourth quarter worth approximately $211,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. This trade represents a 25.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on JNJ shares. Benchmark raised Johnson & Johnson to a “strong-buy” rating in a research report on Thursday, April 24th. The Goldman Sachs Group raised Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price target for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Leerink Partners downgraded shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Eleven investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $170.88.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ opened at $153.17 on Thursday. The firm has a market cap of $368.53 billion, a PE ratio of 23.03, a PEG ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The company’s 50 day moving average price is $155.67 and its two-hundred day moving average price is $153.79.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analysts’ expectations of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be given a dividend of $1.30 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date is Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.39%. Johnson & Johnson’s dividend payout ratio is currently 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.